Novartis sells Enablex US rights for $400 mn

Novartis sells Enablex US rights for $400 mn

Zurich: Novartis is selling the US rights to overactive bladder treatment Enablex to Irish-based pharmaceutical group Warner Chilcott for an upfront payment of $400 million, the Swiss drugmaker said on Friday.

The deal, which also has the potential for additional milestone payments of up to $20 million, is expected to close by the end of October.

Novartis will retain the rights to Enablex, or darifenacin, worldwide except in the United States.

Close